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Abstract
Background
Meta-analyses conducted via the Cochrane Collaboration adhere to strict methodological
and reporting standards aiming to minimize bias, maximize transparency/reproducibility,
and improve the accuracy of summarized data. Whether this results in differences in the
results reported by meta-analyses on the same topic conducted outside the Cochrane Col-
laboration is an open question.
Methods
We conducted a matched-pair analysis with individual meta-analyses as the unit of analy-
sis, comparing Cochrane and non-Cochrane reviews. Using meta-analyses from the cardio-
vascular literature, we identified pairs that matched on intervention and outcome. The pairs
were contrasted in terms of how frequently results disagreed between the Cochrane and
non-Cochrane reviews, whether effect sizes and statistical precision differed systematically,
and how these differences related to the frequency of secondary citations of those reviews.
Results
Our search yielded 40 matched pairs of reviews. The two sets were similar in terms of which
was first to publication, how many studies were included, and average sample sizes. The
paired reviews included a total of 344 individual clinical trials: 111 (32.3%) studies were
included only in a Cochrane review, 104 (30.2%) only in a non-Cochrane review, and 129
(37.5%) in both. Stated another way, 62.5% of studies were only included in one or the
other meta-analytic literature. Overall, 37.5% of pairs had discrepant results. The most com-
mon involved shifts in the width of 95% confidence intervals that would yield a different
PLOS ONE | DOI:10.1371/journal.pone.0144980 December 15, 2015 1 / 17
OPEN ACCESS
Citation: Useem J, Brennan A, LaValley M, Vickery
M, Ameli O, Reinen N, et al. (2015) Systematic
Differences between Cochrane and Non-Cochrane
Meta-Analyses on the Same Topic: A Matched Pair
Analysis. PLoS ONE 10(12): e0144980. doi:10.1371/
journal.pone.0144980
Editor: Neil R. Smalheiser, University of Illinois-
Chicago, UNITED STATES
Received: September 24, 2015
Accepted: November 25, 2015
Published: December 15, 2015
Copyright: © 2015 Useem et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
statistical interpretation of the significance of results (7 pairs). Additionally, 20% differed in
the direction of the summary effect size (5 pairs) or reported greater than a 2-fold difference
in its magnitude (3 pairs). Non-Cochrane reviews reported significantly higher effect sizes
(P< 0.001) and lower precision (P<0.001) than matched Cochrane reviews. Reviews report-
ing an effect size at least 2-fold greater than their matched pair were cited more frequently.
Conclusion
Though results between topic-matched Cochrane and non-Cochrane reviews were quite
similar, discrepant results were frequent, and the overlap of included studies was surpris-
ingly low. Non-Cochrane reviews report larger effect sizes with lower precision than
Cochrane reviews, indicating systematic differences, likely reflective of methodology,
between the two types of reviews that could generate different interpretations of the inter-
ventions under question.
Introduction
In 1972, Archie Cochrane expressed the need for higher quality empirical evidence around the
development of health services.[1] Cochrane believed that randomized controlled trials played
a major role in the development of this evidence, but realized that there was no systematic way
to disseminate results from randomized trials to the professional medical field.[2] As a result,
in 1993, The Cochrane Collaboration was established to conduct meta-analytical reviews on
health care related topics, specifically randomized trials, enabling physicians and other key
decision-makers to access high-quality information on evidence-based results. Because of its
rigorous and analytic methodology, standardization of approaches, and transparency, the
Cochrane Collaboration is often considered to be the gold standard for meta-analytic reviews,
is deemed robust against bias,[3] and is highly trusted by clinicians.[4]
Not infrequently, two or more meta-analyses are independently published on the same
topic, though such studies often fail to reference each other’s findings and may yield conflict-
ing results.[5,6] Reviews conducted within the Cochrane Collaboration follow a standardized
set of methods that non-Cochrane reviews are not bound to. In theory, this might introduce
systematic differences between the two. Several studies provide empirical evidence that
Cochrane reviews tend to be of higher quality, were less vulnerable to bias, acknowledged
more limitations, and were generally more conservative in how the results were endorsed than
non-Cochrane reviews.[7,8] Whether such methodological differences yield different results
is an open question.
To contrast and assess the degree of concordance between Cochrane vs. non-Cochrane
reviews we conducted a matched pair analysis, comparing pairs of meta-analyses from the
Cochrane and non-Cochrane literatures that had examined the same set of interventions and
outcomes. Our analysis had four main objectives. First, we wished to contrast the meta-analy-
ses from the two literatures in terms of sample size, numbers of included subjects, date of publi-
cation, and the degree to which the studies included in each member of the pair overlapped.
Second, we wished to characterize the frequency with which the two literatures conflicted with
each other, in terms of significant differences in the magnitude of effect sizes, shifts in the con-
fidence intervals that would lead to differences in a reader’s interpretation of the results. Third,
we quantified the degree to which the two literatures differed in terms of summary effect size
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and statistical precision. Lastly, we assessed the relationship between how frequently meta-
analyses were cited as a function of whether and how the results between each matched pair
differed.
Methods
Overview
Our analysis compared Cochrane and non-Cochrane meta-analyses that reported on interven-
tional randomized controlled trials within the cardiovascular literature. Our selection of the
cardiovascular literature was to some degree arbitrary, but was influenced by several consider-
ations. First, it has one of the largest collections of meta-analyses, which we surmised could
make it easier to find matches. Second, it is rich in dichotomous outcomes (e.g. myocardial
infarction vs. no myocardial infarction, stroke vs. no stroke, death vs. no death, etc.), which
was helpful given our intention only to focus on dichotomous outcomes and not continuous
variables. Third, it is enriched by a sizeable number of large and methodologically rigorous
source studies focused on well-defined interventions around a relatively narrow range of medi-
cal outcomes.
Search, Inclusion and Matching Strategies
To identify studies for the matched analysis, we employed a search strategy in PubMed using
the following search terms: [("Cochrane database of systematic reviews (Online)"[Journal]
AND (meta analysis [Publication Type]) OR meta-analysis[Publication Type] AND ((((((car-
diovascular[MeSH Terms]) OR cardiovascular disease$[MeSH Terms]) OR cardiology[MeSH
Terms]) OR heart disease$[MeSH Terms]) OR coronary heart disease$[MeSH Terms]) OR
atherosclerosis[MeSH Terms]) OR coronary artery disease$[MeSH Terms]]. The search was
executed on 27 October 2012 and included Cochrane and non-Cochrane reviews.
Meta-analyses from the cardiovascular literature were included if they were comprised of 1)
randomized controlled trials; 2) conducted on human subjects16 years of age; 3) reported a
dichotomous outcome (for ease of working with measures on a risk ratio/odds ratio scale); 4)
reported a common treatment-outcome relationship, and 5) were published after 1996, the year
that the first Cochrane reviews were published, and the year in which the Cochrane Collabora-
tion’s methodology was first posted to theWorld WideWeb.[9] In some cases, we identified
reviews that updated a previously published meta-analysis. In such cases, we only considered
the most recent iteration of that review.
After all inclusion criteria were met, we attempted to match each non-Cochrane meta-anal-
ysis with a comparable Cochrane meta-analysis based on:
1. Disease condition;
2. Intervention;
3. Clinical outcome measured; and
4. Publication within 5 years of each other.
We employed a two-step matching process.
First we had to identify pairs of reviews that focused on the same intervention/outcome
combinations that met inclusion criteria. Because the number of Cochrane reviews is small
compared with non-Cochrane reviews, we found it most efficient to start the matching process
within the Cochrane review, and then seek potential non-Cochrane matches.
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Second, we had to identify identical analyses within each review pair that described the
same intervention and outcomes. Since a given review often includes multiple meta-analyses
addressing several endpoints—and in the case of Cochrane reviews, sometimes dozens of end-
points—we used the following approach to identify matches on specific meta-analyses within
each pair. Because non-Cochrane reviews tend to report fewer outcomes, we started with the
non-Cochrane outcomes and then attempted to match within Cochrane. If the non-Cochrane
meta-analysis had a defined primary endpoint, we used that to match into the Cochrane
review. If more than one primary clinical endpoint was defined, we used a random number
generator to select one, and then attempted to match that to the non-Cochrane paper. If that
failed to yield a match, we moved to the next randomly selected endpoint from the non-
Cochrane paper to seek a Cochrane match, and so forth until a matched anlaysis was made or
all attempts were exhausted.
To avoid putting too much weight on publications that listed multiple potential matches,
we only used a single intervention/outcome combination for each pair of meta-analyses, after
which we moved on to the next matched pair. More simply stated, each member of each pair in
this analysis could only enter our final analytic data set once. This means that our matched pair
analysis represents only a small subset of potential matches between the Cochrane and non-
Cochrane literatures.
Once we had assembled our set of potential matched pairs from the two sets of reviews, the
entire team reviewed the matches to confirm that each pair met our matching criteria, that the
extracted data were correct, and that the direction of the effect size was harmonized (which
could be violated if one analysis had expressed effect size in terms of a protective effect in the
presence of the intervention, whereas the other defined it as harmful effect in the absence of
the intervention). In the few instances when this occurred, we re-calculated the effect sizes so
that all interventions were expressed as a hypothetical risk reduction due to the intervention.
Data Extraction
Given the exploratory nature of this analysis, we had no sample size estimates to guide our
search. Arbitrarily, we aimed to capture 50 matched pairs (or 100 meta-analyses in total),
although in the end we only located 40 matched pairs for the final analysis. The following data
were extracted from each meta-analysis: author, year of publication, disease condition, inter-
vention (treatment), comparison (control), cardiovascular outcome, combined effect estimate,
95% confidence interval, sample size and number of studies included. We made no distinction
between reviews that reported using odds ratios vs. relative risks, and instead took these as
reported in the review. We debated whether to recalculate all results using a common statistic,
but ultimately decided against this, reasoning that the average consumer/reader of a meta-
analysis would be unlikely to recalculate a relative risk as an odds ratio to see if that might har-
monize discrepant results between two reviews. This reasoning also applied to whether one
analysis used a different statistical approach, such as fixed vs. random effects modeling. The
average reader may or may not appreciate the distinctions between these approaches, but in
any case would be exceedingly unlikely to replicate the analyses themselves around a unified
statistical model. Thus, we opted to use the data as reported in the papers, just as a typical
reader would see the results.
Statistical Analyses
Descriptive statistics were used to summarize characteristics of each matched Cochrane and
non-Cochrane pair. We calculated differences in sample sizes, the number of studies included,
and the year of publication between each matched pair. The Wilcoxon two-sample test was
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used to determine if there was a significant difference in the total number of studies and sample
sizes between Cochrane and non-Cochrane reviews. To compare the summary measures of
effects within each matched pair, we displayed Cochrane and non-Cochrane summary esti-
mates and corresponding 95% confidence intervals using Forest plots generated via a macro on
Microsoft Excel.
We identified pairs with discrepant results, and sorted them based on the nature of the dis-
crepancy using the following categories:
1. Changes of the width of 95% confidence intervals that shifts a statistical interpretation of
the meta-analytic result, e.g., one review concludes a statistically significant result and the
other non-significant result.
2. The magnitude of the aggregate effect sizes differed by at least 2-fold (but were in the same
direction).
3. The direction of the effect size was reversed.
To determine if the summary measures of effect differed significantly between Cochrane
and non-Cochrane, we regressed the Cochrane estimate on the matched non-Cochrane esti-
mate on a logarithmic scale using simple linear regression and displayed the results graphically.
We repeated the regression analysis using the standard error (SE) from each member of the
pair to contrast how precision differed between the two review types.
While somewhat controversial, bibliometric measures such as citation rates are widely used
as a proxy for the impact of that paper in the scientific literature.[10,11] To probe the relation-
ship between citation frequencies and discrepant results we used Google Scholar’s search
engine, within each category of discordancy and grouped by Cochrane and non-Cochrane to
identify the number of times a given review was cited by other studies in the literature subse-
quently, and displayed these graphically as box/whisker plots. All statistical analyses used SAS
version 9.2. The final data sets can be accessed on line at S1 Data.
Results
The initial search identified 480 Cochrane cardiovascular meta-analyses, of which 189 were
excluded based on inclusion/exclusion criteria. From the remaining 291 Cochrane Review arti-
cles, we were unable to find a meta-analysis for 251 among the non-Cochrane reviews that
matched on disease condition, intervention, outcome measured, and publication within five
years. Thus, our search process yielded 40 matched pairs of Cochrane and non-Cochrane
meta-analyses that were included in this analysis (Fig 1 and S1 Checklist: PRISMA checklist).
Descriptive statistics of the meta-analyses used in our analyses are shown in Table 1.
Cochrane and non-Cochrane reviews were similar in regards to total number of included stud-
ies and aggregate sample sizes. The Cochrane meta-analyses included a median of 5.5 (inter-
quartile range (IQR): 3.0–8.5) studies, while non-Cochrane meta-analyses included a median
of 6.0 (IQR: 4.5–8.5) studies. The median sample size for Cochrane reviews was 1,368 subjects
(IQR: 500–7,788 subjects), while non-Cochrane had a median of 1,434 subjects (IQR: 535–
10,485 subjects). The Wilcoxon two-sample test yielded no statistically significant differences
between Cochrane and non-Cochrane matches in regards to average sample sizes (p = 0.54)
and numbers of studies (p = 0.41) included in each meta-analysis.
Overall, neither set of reviews dominated in terms of being first to publish. The Cochrane
meta-analysis was published before its non-Cochrane pair in 22 of the 40 pairs, while the non-
Cochrane meta-analysis was published prior to the Cochrane Review in 13 matched pairs. Five
pairs were published in the same year.
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The Cochrane and non-Cochrane reviews included a total of 344 individual clinical trials.
Of these, 111 (32.3%) studies were included only in a Cochrane review, 104 (30.2%) exclusively
in a non-Cochrane review, while 129 (37.5%) had been included in both. Stated another way,
62.5% of studies were only included in one or the other meta-analytic literature, not both. In
six instances (Pairs 9, 10, 21, 26, 27 and 35), the overlap between studies included in matched
pairs of Cochrane and non-Cochrane reviews could not be determined due to insufficient data
within the source paper about which studies had been combined in specific meta-analyses
within the larger review (noted as ‘Indeterminate’ in Table 1).
Fig 1. Study selection process and reasons for exclusion of studies. This figure summarizes the path
taken from identification of 480 Cochrane meta analyses of randomized controlled trials in the cardiovascular
literature through inclusion/exclusion and matching to non-Cochrane reviews to reach our final analytic set of
40 matched pairs of meta-analyses.
doi:10.1371/journal.pone.0144980.g001
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Table 1. Descriptive features of the 40matched Cochrane and non-Cochrane meta-analyses.
Macro differences1 Overlap of studies2
Match
No.
Lead author
(Cochrane
is 1st in each pair)
Year Intervention Outcome Publi-
cation
years*
Sample
sizes*
Included
studies*
Found
in both
Cochrane
only
Non-
Cochrane
only
1 Watson, L. I. 2004 Streptokinase v.
UFH
Clot lysis 3 -62 -4 1 2 6
Wells, Philip S 2001 Streptokinase v.
UFH
Clot lysis
2 Romme, J. J. 2011 Midodrine Vasovagal
syncope
recurrence
2 -87 -2 2 0 2
Liao, Ying 2009 Midodrine Vasovagal
syncope
recurrence
3 Theologou, T. 2011 Preoperative intra
aortic balloon
pump
In-hospital
mortality
3 57 1 2 3 2
Dyub, Adel M. 2008 Preoperative intra
aortic balloon
pump
In-hospital
mortality
4 Liakopoulos, O. J. 2012 Preoperative
Statin Therapy
Atrial fibrilliation 1 0 0 8 0 0
Dong, Lili 2011 Preoperative
Statin Therapy
Atrial fibrilliation
5 Martin-Rendon, E. 2008 Stem cells vs. no
stem cells
Revascularization -1 -583 -5 3 2 4
Zhang, S 2009 Stem cells at 4–7
days vs. none
Revascularization
6 Crystal, E. 2004 Pacing vs. control Atrial fibrilliation -2 -1025 -6 5 3 9
Burgess, DC 2006 Overdrive/Pacing
vs. control
Atrial fibrilliation
7 Vital, F. M. 2008 CPAP vs.
standard care
Mortality 2 82 1 11 1 0
Peter, JV 2006 CPAP vs.
standard care
Mortality
8 Dieleman, J. M. 2011 Corticosteroids Atrial fibrilliation 2 343 0 6 11 1
Marik, Paul E. 2009 Corticosteroids Atrial fibrilliation
9 Hofmeyr, G. J. 2010 Calcium
supplementation
Gestational
hypertension
-1 Indeterminate**
Imdad, A 2011 Calcium
Supplementation
Gestational
hypertension
10 van Dongen, C. J. 2004 LMWH vs. UFH Recurrent Venous
Thromboembolism
1 Indeterminate**
Lorio, A 2003 LMWH vs. UFH Recurrent Venous
Thromboembolism
11 Clifford, DM 2012 Stem Cells Mortality 1 964 12 4 14 2
Tuty Kuswardhani,
R.A.
2011 Stem Cells Mortality
12 Zhang, S. 2010 Trializad Symptomatic
vasospasm
1 1 0 5 0 0
Gyoe, Yeon 2009 Trializad Symptomatic
vasospasm
13 van Dongen, C. J. 2003 Once vs. twice
daily LMWH
Recurrent Venous
Thromboembolism
2 -227 -2 3 0 2
(Continued)
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Table 1. (Continued)
Macro differences1 Overlap of studies2
Match
No.
Lead author
(Cochrane
is 1st in each pair)
Year Intervention Outcome Publi-
cation
years*
Sample
sizes*
Included
studies*
Found
in both
Cochrane
only
Non-
Cochrane
only
Couturaud, F 2001 Once vs. twice
daily LMWH
Recurrent Venous
Thromboembolism
14 Taylor, F. 2011 Statins Mortality 0 -51334 -15 5 3 18
Tonelli, Marcello 2011 Statins Mortality
15 Westendorp, W. F. 2012 Antibiotics Mortality 3 80 1 4 1 0
van de Beek,
Diederick
2009 Antibiotics Mortality
16 Hooper, L. 2004 Omega 3 Fatty
Acids vs. placebo/
no
supplementation
All-Cause Mortality 0 21217 38 6 38 0
Yezbe, D 2004 Omega 3 Fatty
Acids vs. placebo/
no
supplementation
All-Cause Mortality
17 Squizzato, A. 2011 Clopidogrel and
aspirin
Major
cardiovascular
events
-1 -10368 -5 2 0 3
Zouh, YH 2012 Clopidogrel and
aspirin
Major
cardiovascular
events
18 Fahey, T. 2006 Home-monitoring
of blood pressure
Blood pressure
control
2 -362 -2 2 0 4
Cappuccio, FP 2004 Home-monitoring
of blood pressure
Blood pressure
control
19 Wright, J. M. 2009 Beta-Blockers Total
Cardiovascular
Events
3 8754 1 2 3 2
Bradley, Hazel A. 2006 Beta-Blockers Total
Cardiovascular
Events
20 De Schryver, E. L. 2003 Dipyridamole plus
Aspirin v. Aspirin
Alone
Vascular event -2 -831 7 3 7 2
Leonardi-Bee, Jo 2005 Dipyridamole plus
Aspirin v. Aspirin
Alone
Vascular event
21 Hemmingsen, B. 2011 Intensive glycemic
control
Macro vascular
complications
1 Indeterminate**
Hong, Wu 2010 Intensive glycemic
control
Macro vascular
events
22 Akl, E. A. 2007 Anticoagulants 1-year mortality 0 -831 -4 4 1 5
Kuderer, Nicole M 2007 Anticoagulants 1-year mortality
23 Lip, G. Y. 2011 Aspirin Stroke 0 -30740 -7 2 0 7
Bartolucci, Alfred A. 2011 Aspirin Stroke
24 Dong, B. 2006 rt-PA vs. heparin Major hemorrhage -3 0 0 5 0 0
Tardy, B. 2009 rt-PA vs. heparin Major hemorrhage
25 Akl, E. A. 2011 LMWH vs.vitamin
K antagonists
Mortality 2 226 3 3 3 0
(Continued)
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Table 1. (Continued)
Macro differences1 Overlap of studies2
Match
No.
Lead author
(Cochrane
is 1st in each pair)
Year Intervention Outcome Publi-
cation
years*
Sample
sizes*
Included
studies*
Found
in both
Cochrane
only
Non-
Cochrane
only
Louzada, Martha L 2009 LMWH vs. vitamin
K antagonists
Mortality
26 Navaneethan, S. D. 2009 Statin therapy vs.
placebo
Cardiovascular
mortality
-3 Indeterminate**
Palmer, SC 2012 Statin therapy vs.
placebo
Cardiovascular
mortality
27 van der Schaaf, I. 2005 Endovascular
coiling versus
neurosurgical
clipping
Cerebral ischemia 0 Indeterminate**
de Oliviera, JG 2005 Endovascular
coiling versus
neurosurgical
clipping
Symptomatic
Vasospasm
28 Heran, B. S. 2012 ARBs plus ACEi
versus ACEi alone
Mortality 2 -9801 -1 4 3 4
Kuenzli, Andrea 2010 ARBs plus ACEi
versus ACEi alone
Mortality
29 Nesbitt, C. 2011 Radiofrequency
obliteration
Recurrence 3 -15 0 2 1 1
Luebke, Thomas 2008 Radiofrequency
obliteration
Recurrence
30 Nordmann, AJ 2009 Stenting vs.
balloon
angioplasty
6–12 month
mortality
1 -2956 -6 5 1 5
De Luca, Giuseppe 2008 Stenting vs.
balloon
angioplasty
6–12 month
mortality
31 Evers, J. H. 2008 Varicocele surgery
or embolisation
vs. no treatment
Pregnancy Rate -3 227 4 3 0 1
Baazeem, A 2011 Varicocele repair
vs. no treatment
Pregnancy Rate
32 Hoenig, M. R. 2010 Early invasive
(angioplasty) vs.
Conservative
treatment
Index Death or
Non-Fatal MI
2 -3793 -4 4 0 4
O’Donoghue,
Michelle
2008 Early invasive
(angioplasty) vs.
Conservative
treatment
Index Death or
Non-Fatal MI
33 Walters, G. 2008 Plasma exchange Mortality -3 -134 -4 5 0 4
Walsh, Michael 2011 Plasma exchange Mortality
34 Algra, A. 2006 Oral
anticoagulants vs.
antiplatelet
therapy
Major bleeding
complication
-2 -3851 -3 2 1 4
Schachter, ME 2008 Oral anti-
coagulants vs.
antiplatelet
therapy
Major bleeding
complication
(Continued)
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Table 1. (Continued)
Macro differences1 Overlap of studies2
Match
No.
Lead author
(Cochrane
is 1st in each pair)
Year Intervention Outcome Publi-
cation
years*
Sample
sizes*
Included
studies*
Found
in both
Cochrane
only
Non-
Cochrane
only
35 Li, W. 2009 Acanthopanax
versus control
Improvement of
neurological deficit
2 Indeterminate**
Wu, B 2007 Traditional
Chinese patent
medicine
Improvement of
neurological deficit
36 Gabriel, S. R. 2005 Primary and
Secondary
hormone
replacement
therapy and
placebo
Stroke occurrence -1 -7931 3 3 6 3
Magliano, DJ 2006 Hormone therapy
vs. placebo
Stroke occurrence
37 Coward, L. J. 2004 Endovascular
treatment vs.
carotid
endarterectomy
Death or any
stroke after 1 year
-3 -334 -1 2 0 1
Luebke, T 2007 Endovascular
treatment vs.
carotid
endarterectomy
Death or any
stroke after 1 year
38 Rerkasem, K. 2008 Local Anesthesia MI within 30 days 1 3824 3 4 4 1
Guay, J. 2007 Local Anesthesia MI
39 Brooks, S. C. 2011 Mechanical vs.
manual chest
compressions
Return of
spontaneous
circulation
-2 -573 -2 0 2 4
Westfall, Mark 2013 Mechanical vs.
manual chest
compressions
Return of
spontaneous
circulation
40 Moja, L 2012 Trastuzumab Congestive heart
failure
1 -1601 -2 7 1 3
Chen, Tao 2011 Trastuzumab Congestive heart
failure
Notes
1. ‘Macro differences’ refers the differences in the number of years between the two reviews, the total number of subjects, and the number of studies
included.
2. The overlap analysis lists the numbers of studies in each pair that were found in both members, or found uniquely in the Cochrane or non-Cochrane
reviews.
* Differences are [Cochrane minus (non-Cochrane)]. For example, a Cochrane review published in 2003, with 2000 subjects across 5 studies, and a non-
Cochrane published in 2005 with 1000 subjects across 8 studies, would here be summarized as ‘-2’, ‘1000’, and ‘-3’ in the differences in years, subjects
and studies categories, respectively.
** In some instances, a review listed the number of articles included, but did not specify whether all of those papers pertained to a specific meta-analysis
within the larger report., This occurred primarily in the Cochrane reviews. Since it cannot be assumed that every sources paper was included in every sub-
analysis within the overall report, we categorized such instances as ‘indeterminate’ when calculating the macro differences for included studies, sample
slizes, and the overlap analysis. The delta publication year of course was unaffected.
Abbreviations:
ACEI: Angiotensin converting enzyme inhibitor; AF: Atrial fibrillation; ARB: Angiotensin receptor blocker; CHF: Congestive heart failure; CPAP: Continuous
Positive Airway Pressure; IABP: Intra-aortic balloon pump; INR: International normalized ratio; LMWH: Low molecular weight heparin; MI: Myocardial
infarction; PST: Pre-operative statin therapy; rt-PA: Recombinant tissue plasminogen activator; SVT: Supraventricular tachycardia; UFH: Unfractionated
heparin; VKA: Vitamin K antagonist; VTE: Venous thromboembolism.
doi:10.1371/journal.pone.0144980.t001
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The overlap data in Table 1 allowed us to assess the degree to which publication sequence
might account for differences in which studies were included in each member of the matched
pair. For example, one might assume that if a non-Cochrane review was published after a
Cochrane review and included three studies that the Cochrane did not, that this difference
might be explained by studies published subsequent to the first review and only available
for the later review. However, we found a large number of matched pairs that violated that
assumption. We sorted the 32 matched pairs that were neither indeterminate (Pairs 9, 10, 21,
26, 27 and 35) nor 100% overlapping in their included studies (Pairs 4 and 12) into three
groups based on publication sequence. Four pairs were published in the same year (Pairs 14,
16, 22, and 23), of which none had complete overlap. Among the seventeen pairs where the
non-Cochrane review was published first, publication sequence alone could not account for the
lack of overlap for 8 matches (Pairs 1, 2, 13, 18, 28, 30, 32, and 40). Conversely, among the
eleven pairs where the Cochrane review was published first, sequence alone could not account
for the lack of overlap for 3 matches (Pairs 20, 31, and 36). Thus, for 47% (15/32) of matched
and analyzable non-identical pairs, publication sequence alone would not explain the differ-
ences between the lists of included studies between the pairs of Cochrane and non-Cochrane
meta-analyses. This suggests that factors other than publication sequence resulted in differ-
ences in the inclusion/exclusion of studies in the two sets of reviews.
Fig 2 provides Forest plots for the reported effect sizes and 95% confidence intervals for
each matched pair of reviews going from smallest to largest effect sizes. In all of these analyses,
an effect size of 1.0 indicates that the intervention in question had no effect relative to its com-
parator treatment. The paired analyses were comparable though not identical. As summarized
in Table 2, the most frequent discrepancies were shifts in the level of statistical significance due
to positioning of the upper or lower bound of the 95% CI relative to 1.0, such that one meta-
Fig 2. Summary effect sizes for matched Cochrane and non-Cochrane paired meta-analyses. The figure presents Forest plots of effect sizes with 95%
confidence intervals for each pair of Cochrane (left) and non-Cochrane (right) reviews. Each of the 40 matched pairs has been sorted based on effect size
from the Cochrane review in ascending order of effect size.
doi:10.1371/journal.pone.0144980.g002
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analysis suggested a statistically significant effect and its match a non-significant effect. This
occurred in 7 (17.5%) of the matched pairs. Among the matched meta-analyses that agreed
upon the direction of the effect size, 3 (9.1%) differed by at least 2-fold in the magnitude of the
effect size. Of more concern, 5 (12.5%) of the matched pairs included a discrepancy such that
the direction of the effect size, regardless of statistical significance, either reversed in direction
or shifted from a protective to a harmful or null effect, or vice versa. Thus, overall, the results
for 15/40 (37.5%) of the paired meta-analyses disagreed to some degree.
To quantify the degree of concordance between the Cochrane and non-Cochrane litera-
tures, we regressed the summary effect sizes on the logarithmic scale of each pair of reviews
(Fig 3a), and their statistical precision using the standard errors of the corresponding effect
sizes (Fig 3b). For both outcomes, there were systematic differences separating the two types
of reviews. Specifically, non-Cochrane reviews reported significantly larger effect sizes
(t = 13.2; p = 0.0001; F = 7.85; p = 0.0082 (Fig 3a)) and wider standard errors (i.e., lower pre-
cision around the effect size) (t = 5.50; p = 0.0001; F = 13.1; p = 0.0009 (Fig 3b)) than their
matched Cochrane pair.
We determined the number of times the matched Cochrane and non-Cochrane reviews
were cited by other publications as a function of the presence or absence of a discrepant result,
and the category of discrepancy when present (Fig 4). Citation rates were very similar between
Cochrane/non-Cochrane studies when the results were concordant, if the discrepancy was due
to shifts in the 95% confidence intervals, or if the direction of the effect sizes were reversed.
However, when the discrepancy was due to a 2-fold or greater difference in the effect size, the
reviews that reported the larger of the two effect sizes were cited elsewhere 130 times, vs. 32
times for the matched pair reporting the lower effect size.
Table 2. Summary of discrepant results betweenmatchedmeta-analysis pairs from the Cochrane and
non-Cochrane cardiovascular literatures.
Statistical interpretation of the meta
analysis changes due to shifts in
width of 95% CI around ES (N = 7)
Shifts in the magnitude of
ES but in same direction
(2- fold difference) (N = 3)
Shifts in the direction of the
ES (i.e., protective to harmful/
null, or vice versa) (N = 5)
Pair 5: Cochrane non-significant; non-
Cochrane significant
Pair 31: non-Cochrane
ES  2x Cochrane
Pair 11: Cochrane has NS
protective effect; non-Cochrane
has NS neutral/harmful effect
Pair 10: Cochrane significant; non-
Cochrane non-significant
Pair 35: non-Cochrane
ES  2x Cochrane
Pair 29: Cochrane has NS
harmful effect; non-Cochrane
has non significant protective
effect
Pair 16: Cochrane non-significant;
non-Cochrane significant
Pair 39: Cochrane ES  2x
non-Cochrane
Pair 30: Cochrane has NS
harmful effect; non-Cochrane
has non significant protective
effect
Pair 18: Cochrane non-significant;
non-Cochrane significant
Pair 33: Cochrane has NS
harmful effect; non-Cochrane
has neutral effect (~1.0)
Pair 21: Cochrane non-significant;
non-Cochrane significant
Pair 37: Cochrane has NS
harmful effect; non-Cochrane
has neutral effect (~1.0)
Pair 22: Cochrane non-significant;
non-Cochrane significant
Pair 34: Cochrane non-significant;
non-Cochrane significant
Abbreviations: CI = Confidence interval; ES = Effect size; NS = non-significant
doi:10.1371/journal.pone.0144980.t002
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Discussion
The power of meta-analysis lies is its ability to make novel inferences that only emerge when
aggregating multiple similar studies on a given topic. By going up one level of aggregation and
using individual meta-analyses as the unit of analysis instead of individual studies—in effect a
‘meta-meta’ analysis—we have shown that novel inferences may emerge regarding the meta-
analytic literature itself that are only apparent at that higher level of aggregation. Specifically,
we have shown that the Cochrane Collaboration’s approach to meta-analysis often yields dif-
ferent results from matched meta-analyses conducted outside of the Collaboration.
While, the matched Cochrane and non-Cochrane meta-analyses were similar in regards to
average sample size, the number of individual randomized trials included, and being first to
publish, there were frequent differences in the results between the matched Cochrane and non-
Cochrane reviews. The most common discrepancy related to shifts in the statistical interpreta-
tion of the significance of effect sizes that were otherwise quite similar between Cochrane and
non-Cochrane reviews. Such differences are notable given the lamentable tendency of readers
to dichotomize results as ‘significant and therefore believable’ vs. ‘non-significant and therefore
not believable’.[12] Of more concern, a number of reviews reported markedly different effect
sizes, or reported effect sizes that contradicted each other (as from a protective effect to a null
or harmful one, or vice versa). These are all instances where the bottom line interpretation by a
reader of a review could differ qualitatively.
Moreover, the differences between Cochrane and non-Cochrane reviews appear to be sys-
tematic, such that, quantitatively, non-Cochrane reviews report larger effect sizes but with
lower precision than matched Cochrane analyses. This supports an earlier analysis by Tricco
et al, which, while not a matched pair analysis as in this current study, noted that non-
Cochrane reviews were more likely to report positive effects of interventions than Cochrane
reviews.[8] Further investigations looking at the quality of included/excluded studies in each
literature could help clarify this issue. It was also interesting to note that meta-analyses report-
ing substantially larger effect sizes than their matched pair were cited roughly 4-times more
Fig 3. Systematic differences between the Cochrane and non-Cochranematchedmeta-analyses, in terms of a) natural log of effect size, and b)
standard error of effect size. This figure regresses on a natural log scale pairs of Cochrane and non-Cochrane reviews in terms of effect size (Fig 3a) and
standard error (Fig 3b). Each point on the scatter plot represents the intersection point of a Cochrane review with its matched pair in the non-Cochrane
literature. In both cases, using T and F tests, the relationships are strongly correlated. However, in both, the slope of the line reveal that, on average, non-
Cochrane reviews report slightly larger effect sizes but with larger standard errors (i.e., lower precision) than their matched Cochrane review.
doi:10.1371/journal.pone.0144980.g003
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often in the scientific literature. This is consistent with prior observations that studies or meta-
analyses that report larger effect sizes tend to garner more attention in the medical community.
[13,14]
Since a meta-analysis is essentially a weighted average of its component studies, it is logical
to assume that discrepant results might reflect differences in how studies were selected for
Fig 4. Association between different classifications of discrepant results in matched pairs of meta-analyses and the number of times those
analyses were cited elsewhere in the published literature. This figure reports the number of times that Cochrane and non-Cochrane reviews were cited
by other articles in the medical literature using the bibliometric feature in Google Scholar. Each pair of box and whisker plots corresponds to a given category
of reviews. The first pair lists pairs of reviews that were concordant according to our definitions, meaning that the results of the contrasted analyses agreed.
The next three sets of pairs reflect the three different patterns of discrepant results. These were discrepancies based on: shifts in width of confidence
intervals that yield a different interpretation of the significant of the effect size (pair 2); instances where one review reported an effect size at least twice that of
its match (pair 3); and instances where the effect size reverses (pair 4). To note, the numbers of subsequent citations is quite similar between the Cochrane
and non-Cochrane pairs except in the case of discrepancies around the magnitude of the effect size. In those cases, the reviews reporting the larger effect
sizes were cited far more often than those reviews reporting the smaller effect size.
doi:10.1371/journal.pone.0144980.g004
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inclusion/exclusion by each member of a pair. The generally poor overlap in studies included
in the Cochrane and non-Cochrane matched pairs supported this concern. It would be tempt-
ing and convenient to explain this simply as one review being published after the other, and
thus having access to newer studies that could not have been included in the older paper. How-
ever, our results challenged that explanation. First, the two sets of reviews were actually quite
well balanced in terms of which was first to publish. More importantly, our data show that pub-
lication sequence could only be evoked as a possible explanation for differences in the numbers
of included studies in about half of the matched pairs. This argues that these discrepancies are
not simply an artifact of time, but more likely reflect differences in search strategies and/or
inclusion/exclusion of studies, which may differ systematically between the Cochrane and non-
Cochrane literatures.
In other words, our results indicate a substantial divide between the Cochrane and non-
Cochrane literatures. What our analysis does not indicate, of course, is which of these sets of
reviews is more ‘correct’. With that said, the lower level of precision in effect sizes from the non-
Cochrane reviews, combined with lack of standardization of methodology in those reviews,
would tend to place the burden of proof on the non-Cochrane side. While our analysis covers a
very small fraction of the vast body of work that comprises the meta-analytic literature, readers
should be aware that the two types of meta-analyses are not synonymous, and that in some
cases the discrepancies could lead to fundamentally different conclusions about whether a given
intervention is effective or not.
One of our main limitations is that we only analyzed meta-analyses summarizing data from
randomized control trials in the cardiovascular literature, so we cannot comment on whether
these results are typical of other medical fields, or even of different kinds of meta-analyses
within the cardiovascular field (e.g., of continuous outcomes or diagnostic test precision).
Repeating our analysis using meta-analyses from other disciplines could be instructive. We
acknowledge that our decision to allow matching of meta-analyses if published within five
years of each other could allow for evolutions in the field. However, the difficulty in finding
matches at all made it impractical to contract this window. With that said, our overlap analysis
suggests that publication sequence was not the most important determinant of which studies
were included in a given meta-analysis.
A seeming limitation is that we did not re-analyze the individual studies included in each
meta-analysis, but rather took the results from those papers as reported. We defend this deci-
sion reasoning that the typical consumer of meta-analytic reports is unlikely to recalculate the
results of a paper that he/she is reading, but would also take the reported results at face value.
This also applies to the use of different statistical models, such as fixed vs. random effect mod-
els. While such differences could lead to shifts in the precision around estimates, it seems
exceedingly unlikely that the average reader would go to those lengths to see if recalculating the
results would reconcile apparent discrepancies. In other words: our analysis focused only on
how the data were presented to the world, not on how they COULD have been presented if
using different statistical techniques. Lastly, and most importantly, our analysis offers no
insight into which of the two literatures are more likely to provide an unbiased effect size esti-
mate. What we can say is that the results of Cochrane and non-Cochrane reviews frequently
disagree, and that the differences appear to be systematic.
The obvious question now is how do we explain these differences? A finding that particu-
larly surprised us in this analysis was that roughly two-thirds of the articles that had been
included in the matched reviews were only found in one or the other, but not both. While
publication sequence might explain some of this, our overlap analysis showed that this alone
could not account for this difference, and therefore the explanation must lie elsewhere. While
beyond the scope of this paper, several hypotheses can be suggested: Does one or the other
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literature tend to miss non-English language publications?; Do they preferentially search dif-
ferent data bases of studies?; Or are the differences related to stricter quality criteria for inclu-
sion? A systematic evaluation of these and potentially other factors is the logical next step for
investigation.
In conclusion, this analysis shows yet again how challenging it is to reach a unified interpre-
tation of the medical literature. It is evident that the Cochrane Collaboration’s methodology
has many advantages: standardization of methodology, transparency, and the breadth of analy-
ses assessed in one report. Nonetheless, this approach limits the numbers of individuals or
organizations that can commit the time and labor to adhering to the Cochrane Collaboration’s
standards. One consequence of that is to limit the overall number of analyses that are con-
ducted by the Cochrane Collaboration. Given that meta-analyses are indispensible tools in clin-
ical research, the need for meta-analyses conducted outside of the Cochrane Collaboration is
not in dispute. With that said, it is concerning when two meta-analyses addressing the same
question, within a similar time frame, reach different conclusions. How should the average
doctor or health policy maker react when two ‘gold standards’ disagree with each other? That
is an excellent question.
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